ES2139754T3 - 3-PHENYL-2-ISOXAZOLINES AS ANTI-INFLAMMATORY AGENTS. - Google Patents

3-PHENYL-2-ISOXAZOLINES AS ANTI-INFLAMMATORY AGENTS.

Info

Publication number
ES2139754T3
ES2139754T3 ES94927778T ES94927778T ES2139754T3 ES 2139754 T3 ES2139754 T3 ES 2139754T3 ES 94927778 T ES94927778 T ES 94927778T ES 94927778 T ES94927778 T ES 94927778T ES 2139754 T3 ES2139754 T3 ES 2139754T3
Authority
ES
Spain
Prior art keywords
isoxazolines
phenyl
inflammatory agents
dermatitis
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94927778T
Other languages
Spanish (es)
Inventor
Edward F Kleinman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PFIZER
Pfizer Inc
Original Assignee
PFIZER
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PFIZER, Pfizer Inc filed Critical PFIZER
Application granted granted Critical
Publication of ES2139754T3 publication Critical patent/ES2139754T3/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/653—Five-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

ESTA INVENCION SE REFIERE A COMPUESTOS DE 3-ARIL-2ISOXAZOLINAS QUE SON INHIBIDORES SELECTIVOS DE FOSFODIESTERASA TIPO IV (FFDIV). LAS 3-ARIL-2-ISOXAZOLINAS SON UTILES EN EL TRATAMIENTO DE SIDA, ASMA, ARTRITIS, BRONQUITIS, ENFERMEDADES CRONICAS DE OBSTRUCCION PULMONAR, PSORIASIS, RINITIS ALERGICA, DERMATITIS, SHOCK, DERMATITIS ATOPICA, ARTRITIS REUMATOIDE Y OSTEOARTRITIS. ESTA INVENCION TAMBIEN SE REFIERE A COMPOSICIONES FARMACEUTICAS UTILES PARA LO MISMO.THIS INVENTION REFERS TO 3-ARYL-2ISOXAZOLINE COMPOUNDS WHICH ARE SELECTIVE INHIBITORS OF TYPE IV PHOSPHODIESTERASE (FFDIV). 3-ARYL-2-ISOXAZOLINS ARE USEFUL IN THE TREATMENT OF AIDS, ASTHMA, ARTHRITIS, BRONCHITIS, CHRONIC DISEASES OF PULMONARY OBSTRUCTION, PSORIASIS, ALLERGIC RHINITIS, DERMATITIS, SHOCK, ATOPICA DERMATITIS, RHEUMARI AND OSTRUM THIS INVENTION ALSO REFERS TO USEFUL PHARMACEUTICAL COMPOSITIONS FOR THE SAME.

ES94927778T 1993-11-26 1994-10-12 3-PHENYL-2-ISOXAZOLINES AS ANTI-INFLAMMATORY AGENTS. Expired - Lifetime ES2139754T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15724193A 1993-11-26 1993-11-26

Publications (1)

Publication Number Publication Date
ES2139754T3 true ES2139754T3 (en) 2000-02-16

Family

ID=22562909

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94927778T Expired - Lifetime ES2139754T3 (en) 1993-11-26 1994-10-12 3-PHENYL-2-ISOXAZOLINES AS ANTI-INFLAMMATORY AGENTS.

Country Status (12)

Country Link
US (1) US5686434A (en)
EP (1) EP0730587B1 (en)
JP (1) JP2818820B2 (en)
AT (1) ATE187447T1 (en)
CA (1) CA2177375A1 (en)
DE (1) DE69422061T2 (en)
DK (1) DK0730587T3 (en)
ES (1) ES2139754T3 (en)
FI (1) FI945556A7 (en)
GR (1) GR3032506T3 (en)
PT (1) PT730587E (en)
WO (1) WO1995014680A1 (en)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990136A (en) * 1996-08-21 1999-11-23 Pharmacia & Upjohn Company Isoxazoline derivatives useful as antimicrobials
DE59711147D1 (en) * 1996-11-11 2004-01-29 Altana Pharma Ag New imidazo- and oxazolopyridines as phosphodiesterase inhibitors.
EP0966452B1 (en) * 1997-01-17 2003-05-02 Basf Aktiengesellschaft Process for preparing sulphurous 2-chloro-3-(4,5-dihydroisoxazol-3-yl)-benzoic acids
US6022977A (en) 1997-03-26 2000-02-08 Dupont Pharmaceuticals Company Dynamic resolution of isoxazoline thioesters to isoxazoline carboxylic acids
DK1054874T3 (en) * 1998-02-13 2002-12-30 Upjohn Co Substituted aminophenylisoxazoline derivatives useful as antimicrobial agents
DE19852095A1 (en) * 1998-11-12 2000-05-18 Basf Ag Process for the preparation of 2-alkyl-3- (4,5-dihydroisoxazol-3-yl) acylbenzenes
PT1852424E (en) * 1998-05-11 2012-05-07 Basf Se Method for manufacturing isoxazoline-3-yl-acyl benzoles
CA2346396C (en) 1998-10-09 2009-04-28 Janssen Pharmaceutica N.V. 4,5-dihydro-isoxazole derivatives and their pharmaceutical use
CA2715683A1 (en) 1999-08-21 2001-03-01 Nycomed Gmbh Synergistic combination
CN1137888C (en) * 1999-09-17 2004-02-11 株式会社Lgci Inhibitors of caspases
KR100399361B1 (en) 1999-11-04 2003-09-26 주식회사 엘지생명과학 Therapeutic composition comprising caspase inhibitor
DE19953024A1 (en) 1999-11-04 2001-05-10 Merck Patent Gmbh Isoxazole derivatives as phosphodiesterase VII inhibitors
AU2002322720B2 (en) 2001-07-25 2008-11-13 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EA200501548A1 (en) 2003-04-01 2006-02-24 Апплайд Резеч Системз Арс Холдинг Н.В. PHOSPHODYSTERASE INHIBITORS FOR INFERTILITY
KR100594544B1 (en) 2003-08-27 2006-06-30 주식회사 엘지생명과학 Caspase inhibitors containing isoxazoline ring
US7825147B2 (en) 2003-08-29 2010-11-02 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
US20070259874A1 (en) * 2003-11-26 2007-11-08 Palle Venkata P Phosphodiesterase Inhibitors
CA2557166C (en) * 2004-03-26 2015-06-30 Cytokine Pharmasciences, Inc. Compounds, compositions, processes of making, and methods of use related to inhibiting macrophage migration inhibitory factor
BRPI0511070A (en) * 2004-06-17 2007-11-27 Infinity Pharmaceuticals Inc compounds and processes for inhibiting the interaction of bcl proteins with binding partners
ES2370788T3 (en) * 2005-02-07 2011-12-22 Aerocrine Ab CHECK BREATHED BREATH FLOW DURING ANALYSIS.
CN103156845B (en) * 2005-03-15 2015-11-18 翁科诺克斯有限公司 There is the compound of immunoregulatory activity
CN102379684B (en) 2005-04-28 2014-11-19 普罗透斯数字保健公司 Pharma-informatics system
JP2009506069A (en) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド Neurogenesis through modulation of muscarinic receptors
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP1928866A1 (en) 2005-09-05 2008-06-11 Ranbaxy Laboratories Limited Substituted indazoles as inhibitors of phosphodiesterase type-iv
CA2626628A1 (en) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type iv inhibitors
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2068872A1 (en) * 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
KR20090071598A (en) 2006-09-18 2009-07-01 랩터 파마슈티컬 인코포레이티드 Treatment of liver disease by administration of receptor binding protein (RAP) -conjugates
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
MX2009003100A (en) * 2006-09-22 2009-05-11 Ranbaxy Lab Ltd Inhibitors of phosphodiesterase type-iv.
US20100029728A1 (en) * 2006-09-22 2010-02-04 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX2009013293A (en) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders.
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2398500B1 (en) 2009-02-20 2019-03-13 2-BBB Medicines B.V. Glutathione-based drug delivery system
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
ES2942923T3 (en) 2009-05-06 2023-06-07 Laboratory Skin Care Inc Dermal delivery compositions comprising complexes of active agent-calcium phosphate particles and methods of use thereof
CN101781294B (en) * 2010-03-10 2012-02-01 天津药物研究院 Imidazole derivative, and preparation method and application thereof
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
CA3100941C (en) 2011-03-01 2024-03-05 Synergy Pharmaceuticals Inc. Process of preparing guanylate cyclase c agonists
AU2012234393B2 (en) 2011-03-31 2017-02-02 Bayer Cropscience Aktiengesellschaft Herbicidally and fungicidally active 3-phenylisoxazoline-5-carboxamides and 3-phenylisoxazoline-5-thioamides
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
EP2900645B1 (en) * 2012-09-25 2019-08-21 Bayer CropScience AG Herbicidal and fungicidal 3-phenylisoxazolin derivatives
KR102040740B1 (en) * 2012-09-25 2019-11-05 바이엘 크롭사이언스 악티엔게젤샤프트 Herbicidal and fungicidal 5-oxy-substituted 3-phenylisoxazoline-5-carboxamides and 5-oxy-substituted 3-phenylisoxazoline-5-thioamides
EP3718557A3 (en) 2013-02-25 2020-10-21 Bausch Health Ireland Limited Guanylate cyclase receptor agonist sp-333 for use in colonic cleansing
JP2016514671A (en) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase agonists and uses thereof
JP2016514670A (en) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase receptor agonists in combination with other drugs
EA201592263A1 (en) 2013-06-05 2016-05-31 Синерджи Фармасьютикалз, Инк. ULTRASCULAR AGONISTS OF GUANYLACYCLASE C, METHOD OF THEIR RECEIVING AND USING
KR20160042039A (en) 2013-08-09 2016-04-18 알데릭스, 인코포레이티드 Compounds and methods for inhibiting phosphate transport
EP3638665B1 (en) 2017-06-13 2021-07-21 Bayer Aktiengesellschaft Herbicidal 3-phenylisoxazoline-5-carboxamides of tetrahydro and dihydrofuran carboxylic acids and esters
HUE056695T2 (en) 2017-06-13 2022-03-28 Bayer Ag Herbicide 3-phenylisoxazoline-5-carboxamides of tetrahydrofuran and dihydrofuran carboxylic acid amides
US20200369630A1 (en) 2017-08-17 2020-11-26 Bayer Aktiengesellschaft Herbicidally active 3-phenyl-5-trifluoromethylisoxazoline-5-carboxamides of cyclopentylcarboxylic acids and esters
JP7217751B2 (en) 2018-01-25 2023-02-03 バイエル・アクチエンゲゼルシヤフト 3-phenylisoxazoline-5-carboxamides of cyclopentenylcarboxylic acid derivatives exhibiting herbicidal activity
CA3133025A1 (en) 2019-03-12 2020-09-17 Bayer Aktiengesellschaft Herbicidally active 3-phenylisoxazoline-5-carboxamides of s-containing cyclopentenyl carboxylic acid esters
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
JPS62103070A (en) * 1985-10-29 1987-05-13 Mitsui Toatsu Chem Inc Isoxazoline derivative and plant growth regulator
US4912120A (en) * 1986-03-14 1990-03-27 Syntex (U.S.A.) Inc. 3,5-substituted 4,5-dihydroisoxazoles as transglutaminase inhibitors
HU215433B (en) * 1986-04-29 2000-05-28 Pfizer Inc. A method for preparing novel 2-oxo-5-phenylpyrimidine derivatives
IE59813B1 (en) * 1986-05-09 1994-04-06 Warner Lambert Co Styryl pyrazoles, isoxazoles and analogs thereof having activity as 5-lipoxy-genase inhibitors and pharmaceutical compositions containing them
ZA872997B (en) * 1986-05-09 1988-12-28 Warner Lambert Co Novel styryl pyrazoles,isoxazoles and analogs thereof having activity as 5-lipoxygenase inhibitors,pharmaceutical compositions and methods of use therefor
DE3736113A1 (en) * 1987-10-26 1989-05-03 Hoechst Ag DRUGS, PHOSPHORUS-BASED 2-ISOXAZOLINES AND ISOXAZOLES CONTAINING THEREOF, AND METHOD OF PREPARING THESE HETEROCYCLIC COMPOUNDS
US4952700A (en) * 1988-04-25 1990-08-28 W.R. Grace & Co.-Conn. Preparation of isoxazolines and isoxazoles
US4933464A (en) * 1988-04-25 1990-06-12 W. R. Grace & Co.-Conn. Process for forming 3-phenylisoxazolines and 3-phenylisoxazoles
CA2017383A1 (en) * 1989-06-08 1990-12-08 Raymond R. Martodam Use of vanilloids for the treatment of respiratory diseases or disorders
WO1991007177A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Pyrimidone derivatives and analogs in the treatment of asthma or certain skin disorders
GB9007762D0 (en) * 1990-04-05 1990-06-06 Beecham Group Plc Novel compounds
EP0451790A1 (en) * 1990-04-12 1991-10-16 Hoechst Aktiengesellschaft 3,5-disubstituted 2-isoxazolines and isoxazoles, process for their preparation, medicines containing them and their use
DE4026018A1 (en) * 1990-08-17 1992-02-20 Hoechst Ag PLANT-PROTECTIVE AGENTS CONTAINING ISOXAZOLINE OR ISOTHIAZOLINE AND NEW ISOXAZOLINE AND ISOTHIAZOLINE
CA2095429A1 (en) * 1990-11-06 1992-05-07 Paul E. Bender Imidazolidinone compounds
PT100441A (en) * 1991-05-02 1993-09-30 Smithkline Beecham Corp PIRROLIDINONES, ITS PREPARATION PROCESS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE
WO1993007141A1 (en) * 1991-10-11 1993-04-15 Smithkline Beecham Corporation Heterocyclic 3-phenylpyrrolidin-2-ones, their preparation and use for the manufacture of a medicament for inhibiting tumor necrosis factor production

Also Published As

Publication number Publication date
DK0730587T3 (en) 2000-04-10
FI945556A7 (en) 1995-05-27
DE69422061D1 (en) 2000-01-13
JP2818820B2 (en) 1998-10-30
EP0730587A1 (en) 1996-09-11
DE69422061T2 (en) 2000-03-30
ATE187447T1 (en) 1999-12-15
PT730587E (en) 2000-05-31
CA2177375A1 (en) 1995-06-01
WO1995014680A1 (en) 1995-06-01
EP0730587B1 (en) 1999-12-08
FI945556A0 (en) 1994-11-25
US5686434A (en) 1997-11-11
GR3032506T3 (en) 2000-05-31
JPH09500146A (en) 1997-01-07

Similar Documents

Publication Publication Date Title
ES2104424T3 (en) ISOXAZOLINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS.
ES2192192T3 (en) CATECOL DIETS AS SELECTIVE PDE INHIBITORS IV.
ES2154683T3 (en) INDOLES REPLACED AS TYPE IV PHOSPHODIESTERASE INHIBITORS.
CR8254A (en) [1,8] NAFTIDRIN-2-ONAS AND RELATED COMPOUNDS FOR THE TREATMENT OF CHICHOPHRENIA
ES2191320T3 (en) DERIVATIVES OF PIPERAZINE AND ITS USE AS ANTI-INFLAMMATORY AGENTS.
BR0307564A (en) Nicotinamide derivatives useful as pde4 inhibitors
GT200100022A (en) DERIVATIVES OF NICOTINAMIDE BENZOCONDENSADA-HETEROCICLILO USEFUL AS SELECTIVE INHIBITORS OF THE ISOZIMAS PDE4.
MX9405132A (en) TETRAHIDRO PIRAZOLOPIRIDINAS BICICLICAS.
ES2111617T3 (en) CONDENSED PIRIMIDINE DERIVATIVES AND THEIR USE AS ANGIOTENSIN II ANTAGONISTS.
PY0201387A (en) ETHER DERIVATIVES USEFUL AS PDE4 ISOZYME INHIBITORS
DK0730587T3 (en) 3-phenyl-2-isoxazolines as anti-inflammatory agents
PA8543301A1 (en) DERIVATIVES OF DIHIDRO-BENZO (B) (1,4) DIAZEPIN-2 -ONA AS ANTAGONISTS II MGLUR2
ECSP045476A (en) THIAZOLIDINONES, ITS PREPARATION AND ITS USE AS MEDICATIONS
CR7038A (en) AMIDA DERIVATIVES OF TIAZOLILICO, OXAZOLILICO, PIRROLILICO AND IMIDIAZOLILICO ACIDS USED AS INHIBITORS OF THE ISOZIMAS PDE4
UY27976A1 (en) HETEROCYCLIC PIPERAZINES SUBSTITUTED FOR THE TREATMENT OF CHICHOPHRENIA
PA8446301A1 (en) 2-AMINO-6- (4-PHENOXI-2-SUBSTITUTED) -PIRIDINES SUBSTITUTED
MX9504422A (en) BICYCLE TETRAHYDROPIRAZOLOPYRIDINS.
CO5611124A2 (en) BENZOFURAN DERIVATIVES SUBSTITUTED USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS
ES2059320T3 (en) NEW DIARYL ALKANOIDS THAT HAVE ACTIVITY AS LIPOXIGENASE INHIBITORS.
BR0212661A (en) Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation
ECSP003747A (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF PULMONARY DISEASES
CL2021001447A1 (en) Crystal forms a, b, d, i of 1–(6–((6–((1r)–1–hydroxyethyl)–8–isopropylamino)pyrido[3,4–d]pyrimidin–2–yl)amino)– 3-pyridyl)piperazin-2-one; pharmaceutical composition comprising them; and its use to treat rheumatoid arthritis, arteriosclerosis, among other diseases (divisional application 201901420).
PA8642901A1 (en) AMIDAS OF ACID 5 AND 6-AMINOALQUIL INDOL-2-CARBOXILICO 3-SUBSTITUTES AND RELATED ANALOGS AS INHIBITORS OF CASEINA CINASA I
MX9603943A (en) ISOXAZOLINE COMPOUNDS AS 5-LIPOOXIGENASE INHIBITORS.
ECSP993278A (en) 4,5 PIRAZINOXINDOLES

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 730587

Country of ref document: ES